| | |
Summary: COMPREHENSIVE SDSU-UCSD CANCER CENTER
PARTNERSHIP
NCI Grants #U54 CA132384 and #U54 CA132379
Project Period: 9/1/2008 8/31/2013
Full Projects
Funded Full Projects
EVALUATION OF NOVEL SANSALVAMIDE A DERIVATIVES AS POTENTIAL ANTI-
CANCER AGENTS
Minority Institution Co-Leader Cancer Center Co-Leader
Shelli R. McAlpine, Ph.D
Professor
Dept. of Chemistry
Stephen B. Howell, M.D.
Professor
Dept. of Medicine
Abstract
Cisplatin is one of the most important cancer chemotherapeutic agents. It is widely used for the
treatment of ovarian, lung, head and neck and several other types of tumors. However, almost all
patients eventually become resistant to cisplatin due, in part, to a failure of the drug to enter the
tumor cells. How this drug enters cells and is distributed to its sites of action within the cell is
|
